Volitionrx Limited (VNRX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
VolitionRx Announces Third Quarter 2015 Financial Results and Business Update
November 4, 2015 6:30 AM ESTNAMUR, Belgium, Nov. 4, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the third quarter ended September 30, 2015.
Third Quarter 2015 and Recent Company Highlights:
Released interim data from an on-going 4,800-subject double blind clinical trial revealing NuQ® blood tests detect 81% of colorectal cancers (CRC) and 67% of high risk... More